On 18 September 2026, Sandoz and mAbxience announced they have entered a licensing, development, manufacturing and commercialisation agreement in relation to a biosimilar to Roche/Chugai’s Hemlibra® (emicizumab). The biosimilar is in early stage development and will be the first haemophilia medicine in the Sandoz biosimilar pipeline.
While the financial terms of the agreement are confidential, the agreement provides Sandoz with the exclusive global commercialisation rights for the emicizumab biosimilar, excluding Argentina, Uruguay and Paraguay. mAbxience has responsibility for biosimilar development and manufacturing.
Sandoz’s collaboration with mAbxience follows its August 2026 agreement with Shanghai Henlius for up to 10 biosimilars, including cetuximab (HLX05-N), evolocumab (HLX16) and belimumab, and its March 2026 agreement with Samsung Bioepis for up to 5 biosimilars, including vedolizumab (SB36). These agreements represent steps in Sandoz’s strategy to expand its biosimilar portfolio to 100+ by 2040 and to maximise value in the “golden decade” for biosimilars, with medicines worth more than USD 650 billion set to lose exclusivity.
Biosimilar emicizumab is being developed by Alvotech, which announced a licensing and commercialisation agreement with Lotus Pharmaceutical in August 2026 including for AVT87 (emicizumab) in the US and eight Asian markets. CSPC Pharmaceutical Group, announced in March 2026 that China’s National Medical Products Administration approved clinical trials for its biosimilar emicizumab (SYS6053). Prestige BioPharma has a preclinical emicizumab biosimilar in its pipeline.